Multiple sclerosis (OMIM 126200) is an inflammatory demyelinating disorder of the central nervous system that is a common cause of chronic neurological disability.^[@R1],[@R2]^ It has its greatest prevalence amongst individuals of Northern European ancestry^[@R3]^ and is moderately heritable,^[@R4]^ with a sibling relative recurrence risk (λ~s~) of \~ 6.3.^[@R5]^ Aside from the early success in demonstrating the important effects exerted by variants in the Human Leukocyte Antigen (HLA) genes from the Major Histocompatibility Complex (MHC),^[@R6]^ there was little progress in unravelling the genetic architecture underlying multiple sclerosis susceptibility prior to the advent of genome-wide association studies (GWAS). Over the last decade, our Consortium has performed several GWAS and meta-analyses in large cohorts, ^[@R7]-[@R10]^ cumulatively identifying more than 50 non-MHC susceptibility alleles. As in other complex diseases, available data suggest that many additional susceptibility alleles remain to be identified.^[@R11]^

The striking overlap in the genetic architecture underlying susceptibility to autoimmune diseases^[@R9],[@R10],[@R12],[@R13]^ prompted the collaborative construction of the "ImmunoChip" (see [Supplementary Note and Supplementary Figs. 1 and 2](#SD2){ref-type="supplementary-material"} for details of IMSGC nominated content), an efficient genotyping platform designed to deeply interrogate 184 non-MHC loci with genome-wide significant associations to at least one autoimmune disease and provide lighter coverage of other genomic regions with suggestive evidence of association.^[@R14]^ Here, we report a large-scale effort that leverages the ImmunoChip to detect association with multiple sclerosis susceptibility and refine these associations via Bayesian fine-mapping.

After stringent quality control (QC), we report genotypes on 28,487 individuals of European ancestry (14,498 multiple sclerosis subjects, 13,989 healthy controls) that are independent of previous GWAS efforts. We supplemented these data with 10,102 independent control subjects provided by the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)^[@R15]^ bringing the total to 38,589 individuals (14,498 multiple sclerosis subjects and 24,091 healthy controls). We performed variant level QC, population outlier identification, and subsequent case-control analysis in 11 country-organized strata. To account for within-stratum population stratification we used the first five principal components as covariates in the association analysis. Per stratum odds ratios (OR) and respective standard errors (SE) were then combined with an inverse variance meta-analysis under a fixed effects model. In total we tested 161,311 autosomal variants that passed QC in at least two of the 11 strata (Online Methods). A circos plot^[@R16]^ summarising the results from this discovery phase analysis is shown in [Figure 1](#F1){ref-type="fig"}.

We defined an *a priori* discovery threshold of p-value \<1 × 10^-4^ and identified 135 primary statistically independent association signals; 67 in the designated fine-mapping regions and 68 in less densely covered regions selected for deep replication of earlier GWAS. Another 13 secondary and 2 tertiary statistically independent signals were identified by forward stepwise logistic regression. A total of 48 of the 150 statistically independent association signals ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) reached a genome-wide significance p-value \<5 × 10^-8^ at the discovery phase alone. Next, we replicated our findings in 14,802 multiple sclerosis subjects and 26,703 healthy controls with available GWAS data imputed to the 1000 Genomes European phase I (a) panel (Online Methods). Finally, we performed a joint analysis of the discovery and replication phases.

We identified 97 statistically independent SNPs meeting replication criteria (p~replication~ \< 0.05, p~joint~ \< 5 × 10^-8^, and p~joint~ \< p~discovery~); 93 primary signals ([Supplementary Figs. 3-95](#SD2){ref-type="supplementary-material"}) and four secondary signals. Of these, 48 are novel to multiple sclerosis ([Table 1](#T1){ref-type="table"}) and 49 correspond to previously identified multiple sclerosis effects ([Table 2](#T2){ref-type="table"}). An additional 11 independent SNPs showed suggestive evidence of association (p~joint~ \< 1 × 10^-6^) ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}).

The strongest novel association, rs12087340 (p~joint~ = 1.1 × 10^-20^, OR = 1.21), lies between *BCL10* (B-cell CLL / lymphoma 10) and *DDAH1* (dimethylarginine dimethylaminohylaminohydrolase 1). The protein encoded by *BCL10* contains a caspase recruitment domain (CARD) and has been shown to activate NF-kappaB.^[@R17]^ The latter is a signalling molecule that plays an important role in controlling gene expression in inflammation, immunity, cell proliferation, and apoptosis. It has been pursued as a potential therapeutic target for multiple sclerosis.^[@R18]^ *BCL10* is also reported to interact with other CARD domain containing proteins including *CARD11*.^[@R19]^ We have also identified a novel association of rs1843938 (p~joint~ = 1.2 × 10^-10^, OR = 1.08), which is only 30 kb from *CARD11*.

One novel SNP was found within an exon, rs2288904 (p~joint~ = 1.6 × 10^-11^, OR= 1.10); a missense variant in *SLC44A2* (solute carrier family 44, member 2). Notably, this variant is also reported as a monocyte-specifccis-acting eQTL for the antisense transcript of the nearby *ILF3* (interleukin enhancer binding factor 3).^[@R20]^ This protein was first discovered to be a subunit of a nuclear factor found in activated T-cells, which is required for T-cell expression of *IL2*, an important molecule regulating many aspects of inflammation.

Of the 49 previously identified effects,^[@R9],[@R10],[@R21]^ 37 are in designated fine-mapping regions, and 23 of these 37 signals were localized to a single gene based on genomic position ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Recognizing that proximity does not necessarily indicate functional importance, this emphasizes the utility of dense mapping in localizing signals from a genome-wide screen. The ImmunoChip analysis furthered the understanding of previously proposed secondary signals at three loci ([Supplementary Note and Supplementary Tables 4-6](#SD2){ref-type="supplementary-material"}); in particular we showed that the effects of two previously proposed independent associations at the *IL2RA* locus are driven by a single variant, rs2104286.^[@R7],[@R22]^.

In an effort to define the functionally relevant variants underlying these associations, we further studied the regions surrounding the 97 associated SNPs using both a Bayesian and frequentist approach in 6,356 multiple sclerosis subjects and 9,617 healthy controls from the UK (Online Methods).^[@R23]^ Based on imputation quality, fine-mapping was possible in 68 regions ([Supplementary Table 7](#SD2){ref-type="supplementary-material"}): 66 of 93 primary ([Fig. 2A](#F2){ref-type="fig"}) and two of four secondary. Eight of the 68 regions were fine-mapped to high resolution ([Table 3](#T3){ref-type="table"}, [Fig. 2B](#F2){ref-type="fig"} and [Supplementary Fig. 96](#SD2){ref-type="supplementary-material"}). One third of the variants identified in these eight regions were imputed, indicating reliance on imputation even with dense genotyping coverage.

To assess whether functional annotation^[@R24]^ provides clues about the molecular mechanisms associated with genetic risk, we considered the relationship of variants to described coding and regulatory features in these eight regions. Although we found no variants with missense or nonsense effects, there was a notable enrichment for variants with functional effects: one known to affect splicing,^[@R25]^ three known to correlate with RNA or serum protein levels^[@R22],[@R26],[@R27]^ and several in transcription-factor binding and DNase I hypersensitive sites.^[@R28],\ [@R29]^ Four of the 18 variants in the fine-mapped regions are within conserved regions (GERP \> 2).^[@R30]^ This lack of functional annotation likely reflects the limited repertoire of reference expression and epigenomic profiles and suggests that the function of the variants may be cell-type or cell-state specific, as has been reported for many eQTLs in immune cell types.^[@R20]^

To determine the Gene Ontology (GO) processes of the 97 associated variants, we used MetaCore from Thomson Reuters (Online Methods). We found the majority of the 97 variants lie within 50 kb of genes having immunological function. Of the 86 unique genes represented, 35 are linked to the GO immune system process ([Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}). We do not see a substantial over- or under- representation of certain GO processes when comparing the novel and previously identified loci, but this may be a limitation of ImmunoChip targeting genomic loci enriched for immunologically active genes, with more subtle distinctions between them not adequately captured by broad annotations such as GO.

Finally, we explored the overlap between our findings and those in autoimmune diseases with reported ImmunoChip analyses. We calculated the percentage of multiple sclerosis signals (110 non-MHC, [Supplementary Table 8](#SD2){ref-type="supplementary-material"}) overlapping those of other autoimmune diseases by requiring an r^2^ ≥ 0.8 between the best variants reported in each study using SNAP.^[@R31]^ In total we find that \~22% of our signals overlap at least one other autoimmune disease. More specificially, \~9.1% overlap with inflammatory bowel disease (IBD) - \~7.3% with ulcerative colitis (UC), \~9.1% with Crohn's disease (CD) -^[@R15]^, \~9.1% with primary biliary cirrhosis (PBC),^[@R32],\ [@R33]^ \~4.5% with celiac disease (CeD),^[@R34]^ \~4.5% with rheumatoid arthritis (RhA),^[@R35]^ \~0.9% with psoriasis (PS),^[@R36]^ and \~2.7% with autoimmune thyroid disease (AITD).^[@R37]^ We report the same top variant seen in PBC for 7 loci. We also note that our best *TYK2* variant (rs34536443)^[@R38]^ is also the most associated variant for PBC, PS and RhA. Lastly, AITD, CeD, PBC, and RhA report variants with pairwise r^2^ ≥ 0.8 to the multiple sclerosis variant near *MMEL1*^[@R39]^ ([Supplementary Table 8](#SD2){ref-type="supplementary-material"}).

In summary, we have identified 48 new multiple sclerosis susceptibility variants. These novel loci expand our understanding of the immune system processes implicated in multiple sclerosis. We estimate that the 110 non-MHC established risk variants explain 20% of the sibling recurrence risk; 28% including the already identified MHC effects^[@R9]^ ([Supplementary Note](#SD2){ref-type="supplementary-material"}). Additionally, we have identified five regions where consistent high resolution fine-mapping implicated one variant which accounted for more than 50% of the posterior in previously identified regions of *TNFSF14, IL2RA, TNFRSF1A, IL12A*, and *STAT4*. Our study further implicates NF-kappaB in multiple sclerosis pathobiology^[@R18]^, emphasizes the value of dense fine-mapping in large follow-up data sets, and exposes the urgent need for functional annotation in relevant tissues. Understanding the implicated networks and their relation to environmental risk factors will promote the development of rational therapies and may enable the development of preventive strategies.

Online Methods {#S1}
==============

ImmunoChip data (discovery set) {#S2}
-------------------------------

Details of case ascertainment, processing and genotyping for the discovery phase are provided in the [Supplementary Note (Supplementary Table 9)](#SD2){ref-type="supplementary-material"}. Genotype calling for all samples was performed using Opticall.^[@R40]^ Samples that performed poorly or were determined to be related were removed ([Supplementary Table 10](#SD2){ref-type="supplementary-material"}). The data were organized in 11 country level strata: ANZ (Australia + New Zealand), Belgium, Denmark, Finland, France, Germany, Italy, Norway, Sweden, United Kingdom (UK), and the United States of America (USA). SNP level quality control ([Supplementary Table 11](#SD2){ref-type="supplementary-material"}) and population outlier identification using principal components analysis ([Supplementary Fig. 97](#SD2){ref-type="supplementary-material"}) were done in each stratum separately.

Discovery set analysis {#S3}
----------------------

We applied logistic regression, assuming a per-allelic genetic model per data set, including the first five principal components as covariates to correct for population stratification ([Supplementary Table 12](#SD2){ref-type="supplementary-material"} lists the per data set genomic inflation factors, λ). We then performed an inverse-variance meta-analysis of the 11 strata, under a fixed effects model, as implemented in PLINK.^[@R41]^ To be more conservative and account for any residual inflation in the test statistic, we applied the genomic control equivalent to the per-SNP standard error in each stratum. Specifically, we corrected the SNP standard errors by multiplying them with the square root of the raw genomic inflation factor λ, per data set, if the λ was \>1.

Within the designated fine-mapping intervals, we applied a forward stepwise logistic regression to identify statistically independent effects. The primary SNP in each interval was included as a covariate, and the association analysis was repeated for the remaining SNPs. This process was repeated until no SNPs reached the minimum level of significance (p-value \<1 × 10^-4^). Outside of the designated fine-mapping intervals, all SNPs having a p-value \<1 × 10^-4^ were identified and grouped into sets based on a physical distance of less than 2Mb and a similar stepwise regression model was applied. Any SNPs to enter the model with p-value \<1 × 10^-4^ after conditioning were considered statistically independent primary signals.

In addition, because of the close physical proximity between some fine-mapping intervals and SNP sets, independence was tested for all identified signals within 2Mb of one another. The and cluster plots ([Supplementary Fig. 98](#SD2){ref-type="supplementary-material"}) of all independent SNPs were examined, and the SNP was excluded if unsatisfactory. If any SNP was excluded, the forward stepwise logistic regression within that fine-mapping interval or SNP set was repeated after removal of the SNP. During this process, 17 additional SNPs were excluded based on cluster or forest plot review.

Replication Set {#S4}
---------------

The replication phase included GWAS data organized into 15 strata. Within each stratum, poorly performing samples (call rate \< 95%, gender discordance, excess heterozygosity) and poorly performing SNPs (Hardy-Weinberg equilibrium (HWE) p-value \<1 × 10^-6^, minor allele frequency (MAF) \< 1%, call rate \< 95%) were removed. Principal components analysis was performed to identify population outliers per stratum, and the genomic control inflation factor was \< 1.1 for each. The data included in the final discovery and replication analyses are summarized in [Supplementary Table 13 and Supplementary Table 14](#SD2){ref-type="supplementary-material"}. All the samples used in the replication set were unrelated to those in the discovery set; verified by identity-by-descent analysis.

We attempted replication of all non-MHC independent signals that reached a discovery p-value of \<1 × 10^-4^ in a meta-analysis set of GWAS. Each data set was imputed to the 1000 Genomes European phase I (a) panel using BEAGLE^[@R42]^ to maximize the overlap between the Immunochip SNP content and the GWAS data. Post-imputation genotypic probabilities were used in a logistic regression model, per stratum, to estimate SNP effect sizes and p-values. By using the post-imputation genotypic probabilities, we penalized SNPs that didn't have good imputation quality, thus ensuring a conservative analysis. Furthermore, we accounted for population stratification in each data set by including the first five principal components in the logistic model. We then meta-analysed the effect size and respective standard errors of the 15 strata using a fixed effects model inverse-variance method. We applied the genomic control equivalent to the per-SNP standard error in each stratum, controlling for the respective genomic inflation factor λ ([Supplementary Table 14](#SD2){ref-type="supplementary-material"}).

To replicate the primary SNPs per identified signal in the discovery phase, we used the replication effect size and respective standard error. For the secondary and tertiary SNPs, we fitted the same exact models as in the discovery phase, per data set. We then performed fixed effects meta-analysis to estimate an effect size that corresponds to the same logistic model. In the case that a SNP was not present in the replication set, we replaced it with a perfectly tagging SNP, i.e. a SNP that had r^2^ and D' equal to 1. If a perfectly tagging SNP was not available, we selected a SNP that had equivalent MAF and the highest possible r^2^ and D'. Estimation of r^2^ and D' for this objective were based on the ImmunoChip control samples.

Joint analysis (discovery and replication sets) {#S5}
-----------------------------------------------

The discovery and replication phase effect sizes and respective standards errors were meta-analysed under a fixed effects model. A SNP was considered replicated when all three of the following criteria were met: 1) replication p-value \<5.0 × 10^-2^, 2) joint p-value \<5 × 10^-8^, and 3) the joint p-value was more statistically significant than the discovery p-value. SNPs that reached a p-value of \<1 × 10^-6^ but did not pass the genome-wide threshold, were coined suggested if the above criteria 1) and 3) were met.

Fine-mapping of association signals {#S6}
-----------------------------------

To fine-map signals of association we used a combination of imputation and Bayesian methodology.^[@R23]^ Around each of the 97 associated SNPs, 2Mb were isolated in the discovery and replication phase UK data as well as the European samples from the Phase 1 1000G.^[@R28]^ Forming the single largest cohort, only UK samples were considered to minimize the effects of differential imputation quality between populations of different ancestry. In addition to the previous quality control, SNPs with failed alignment or a difference in MAF \> 10% between the typed cohorts and the 1000G samples, MAF \< 1%, or HWE p-value \<1.0 × 10^-4^ were removed.

Imputation was performed separately for the UK discovery and replication cohorts on each 2Mb region using the default settings of IMPUTEv2.^[@R43],[@R44]^ Missing genotypes in the genotyped SNPs were not imputed, and any imputed SNP that failed the HWE and MAF threshold was subsequently removed. We carried out frequentist and Bayesian association tests on all SNPs in each cohort separately, assuming additivity, using the default settings of SNPTESTv2.^[@R45]^ Frequentist fixed-effect meta-analysis was carried out using the software META.^[@R46]^ Bayesian meta-analysis was carried out using an independence prior (near-identical results were obtained using a fixed-effect Bayesian meta-analysis).

To identify regions where reliable fine-mapping could be achieved, we used the information score (INFO, obtained from IMPUTEv2) as identified from the 1000G samples. Specifically, we measured the fraction of variants with both *r*^2^ \> 0.5 and *r*^2^ \> 0.8 to the primary associated variant, having greater than 50% and 80% INFO scores respectively. Regions where any SNP with *r*^2^ \> 0.5 had INFO \< 50% were excluded. We also excluded regions where the top hit from imputation had an INFO score less than 80%. Regions were considered to be fine-mapped with high quality when all variants with *r*^2^ \> 0.8 had at least 80% INFO. Within these regions, we excluded variants where the inferred direction of association was opposite in the UK discovery and replication cohorts.

To measure the posterior probability that any single variant drives association, we calculated the Bayes Factor. Under the assumption that there is a single causal variant in the region, this is proportional to the probability that the variant drives the association.^[@R23]^ We identified the smallest set of variants that contained 90% and 50% of the posterior probability. We called a region successfully and consistently fine-mapped if there were at most five variants in the 50% confidence interval and the top SNP from the frequentist analysis lived in the 90% confidence interval. For these regions, we annotated variants with information about evolutionary conservation, predicted coding consequence, regulation, published associations to expression or DNase I hypersensitive sites using ANNOVAR,^[@R47]^ VEP,^[@R24]^ and the eQTL browser, a recent immune cell expression study^[@R20]^, and other literature.

Gene Ontology {#S7}
-------------

To determine the GO processes for which our associated variants were involved, we used MetaCore from Thomson Reuters. We annotated the processes for the unique genes within 50Kb of the variants.

Cross disease comparison {#S8}
------------------------

In order to explore the potential overlap with variants identified across other autoimmune diseases, we calculated the percentage overlap of reported variants found in other ImmunoChip reports to our ImmunoChip results. The top variants reported as either novel or previously known in other ImmunoChip reports were compared with the 110 variants representing both our novel and previous discoveries in multiple sclerosis. In order for a signal to be considered as overlapping, we required an r^2^ ≥ 0.8 using the Pairwise LD function of the SNAP tool in European samples.^[@R31]^

Secondary analyses {#S9}
------------------

We performed a severity based analysis of MSSS in cases only from the discovery phase ([Supplementary Fig. 99](#SD2){ref-type="supplementary-material"}). In addition, a transmission disequilibrium test was done in 633 trios to test for transmission of the 97 identified risk alleles ([Supplementary Fig. 100](#SD2){ref-type="supplementary-material"}). Details are given in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.
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![Discovery phase results\
Primary association analysis of 161,311 autosomal variants in the discovery phase (based on 14,498 cases and 24,091 healthy controls). The outer most track shows the numbered autosomal chromosomes. The second track indicates the gene closest to the most associated SNP meeting all replication criteria. Previously identified associations are indicated in grey. The third track indicates the physical position of the 184 fine-mapping intervals (green). The inner most track indicates −log(p) (two-sided) for each SNP (scaled from 0-12 which truncates the signal in several regions, see [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Additionally, contour lines are given at the *a priori* discovery(−log(p) = 4) and genome-wide significance (-log(p) = 7.3) thresholds. Orange indicates -log(p) ≥ 4 and \< 7.3, while red indicates −log(p) ≥ 7.3. Details of the full discovery phase results can be found in ImmunoBase.](nihms521200f1){#F1}

![Bayesian fine-mapping within primary regions of association\
a) Summary of the extent of fine-mapping across 66 regions in 9,617 healthy controls from the UK, showing the the physical extent of, the number of variants, and the number of genes spanned by the posterior 90% and 50% credible sets. b) Detail of fine-mapping in region of *TNFSF14*. Above the x-axis indicates the Bayes Factor summarizing evidence for association for the SNPs prior to conditioning (blue markers) while below the x-axis indicates the Bayes Factor after conditioning on the lead SNP (rs1077667). Mb=Megabases.](nihms521200f2){#F2}
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48 Novel non-MHC susceptibility loci associated with multiple sclerosis at a genome-wide significance level

                                               Discovery   Replication   Joint                                                                                                     
  -------------------------------------------- ----------- ------------- ------- ------ --------------- ------ ------ --------------- ------ --------------- ------ -------------- ------------
  rs3007421                                    1           6530189       A       0.12   9.6 × 10^-7^    1.12   0.13   8.8 × 10^-5^    1.10   4.7 × 10^-10^   1.11   *PLEKHG5*      intronic
  rs12087340                                   1           85746993      A       0.09   5.1 × 10^-12^   1.22   0.09   2.9 × 10^-10^   1.20   1.1 × 10^-20^   1.21   ***BCL10***    intergenic
  rs11587876                                   1           85915183      A       0.79   8.4 × 10^-8^    1.12   0.81   2.9 × 10^-3^    1.06   4.4 × 10^-9^    1.09   *DDAH1*        intronic
  rs666930                                     1           120258970     G       0.53   7.5 × 10^-8^    1.09   0.53   1.3 × 10^-5^    1.07   6.0 × 10^-12^   1.08   *PHGDH*        intronic
  rs2050568                                    1           157770241     G       0.53   1.3 × 10^-6^    1.08   0.54   2.3 × 10^-5^    1.07   1.5 × 10^-10^   1.08   *FCRL1*        intronic
  rs35967351                                   1           160711804     A       0.67   1.7 × 10^-6^    1.09   0.68   5.9 × 10^-6^    1.09   4.4 × 10^-11^   1.09   ***SLAMF7***   intronic
  rs4665719                                    2           25017860      G       0.25   6.8 × 10^-6^    1.09   0.25   1.1 × 10^-4^    1.08   3.1 × 10^-9^    1.08   *CENPO*        intronic
  rs842639                                     2           61095245      A       0.65   1.7 × 10^-9^    1.11   0.67   1.4 × 10^-6^    1.09   2.0 × 10^-14^   1.10   *FLJ16341*     ncRNA
  rs9967792                                    2           191974435     G       0.62   1.8 × 10^-9^    1.11   0.64   1.2 × 10^-4^    1.07   3.5 × 10^-12^   1.09   ***STAT4***    intronic
  rs11719975                                   3           18785585      C       0.27   5.4 × 10^-6^    1.09   0.28   4.1 × 10^-4^    1.07   1.1 × 10^-8^    1.08                  intergenic
  rs4679081                                    3           33013483      G       0.52   1.2 × 10^-5^    1.08   0.55   3.7 × 10^-4^    1.07   2.2 × 10^-9^    1.07   ***CCR4***     intergenic
  rs9828629                                    3           71530346      G       0.62   5.5 × 10^-6^    1.08   0.64   8.5 × 10^-6^    1.08   1.9 × 10^-10^   1.08   ***FOXP1***    intronic
  rs2726518                                    4           106173199     C       0.55   1.2 × 10^-5^    1.09   0.58   4.7 × 10^-4^    1.06   3.9 × 10^-8^    1.07   ***TET2***     intronic
  rs756699                                     5           133446575     A       0.87   3.0 × 10^-6^    1.12   0.88   6.5 × 10^-6^    1.11   8.8 × 10^-11^   1.12   ***TCF7***     intergenic
  none[c](#TFN6){ref-type="table-fn"}          5           141506564     C       0.61   6.0 × 10^-5^    1.07   0.62   1.5 × 10^-5^    1.08   3.6 × 10^-9^    1.07   *NDFIP1*       intronic
  rs4976646                                    5           176788570     G       0.34   1.0 × 10^-12^   1.13   0.36   5.0 × 10^-7^    1.10   4.4 × 10^-18^   1.12   *RGS14*        intronic
  rs17119                                      6           14719496      A       0.81   1.9 × 10^-6^    1.11   0.80   1.2 × 10^-5^    1.10   1.0 × 10^-10^   1.10                  intergenic
  rs941816                                     6           36375304      G       0.18   4.5 × 10^-9^    1.13   0.20   8.3 × 10^-5^    1.08   3.9 × 10^-12^   1.11   *PXT1*         intronic
  rs1843938                                    7           3113034       A       0.44   2.2 × 10^-6^    1.08   0.44   1.1 × 10^-5^    1.08   1.2 × 10^-10^   1.08   ***CARD11***   intergenic
  rs706015                                     7           27014988      C       0.18   1.3 × 10^-9^    1.14   0.18   9.9 × 10^-3^    1.06   1.1 × 10^-9^    1.10                  intergenic
  rs917116                                     7           28172739      C       0.20   2.1 × 10^-8^    1.12   0.21   5.8 × 10^-3^    1.06   3.3 × 10^-9^    1.09   *JAZF1*        intronic
  rs60600003                                   7           37382465      C       0.10   2.5 × 10^-8^    1.16   0.10   4.2 × 10^-7^    1.14   6.0 × 10^-14^   1.15   *ELMO1*        intronic
  rs201847125[d](#TFN7){ref-type="table-fn"}   7           50325567      G       0.70   2.9 × 10^-8^    1.11   0.70   6.7 × 10^-5^    1.09   1.2 × 10^-11^   1.10   ***IKZF1***    intergenic
  rs2456449                                    8           128192981     G       0.36   2.2 × 10^-8^    1.10   0.37   3.8 × 10^-3^    1.05   1.8 × 10^-9^    1.08                  intergenic
  rs793108                                     10          31415106      A       0.50   5.6 × 10^-8^    1.09   0.51   1.8 × 10^-5^    1.07   6.1 × 10^-12^   1.08                  intergenic
  rs2688608                                    10          75658349      A       0.55   6.4 × 10^-5^    1.07   0.56   2.0 × 10^-4^    1.06   4.6 × 10^-8^    1.07   *C10orf55*     intergenic
  rs7120737                                    11          47702395      G       0.15   7.6 × 10^-8^    1.13   0.15   1.0 × 10^-3^    1.08   1.0 × 10^-9^    1.10   *AGBL2*        intronic
  rs694739                                     11          64097233      A       0.62   1.3 × 10^-5^    1.08   0.62   3.8 × 10^-5^    1.07   2.0 × 10^-9^    1.07   ***PRDX5***    intergenic
  rs9736016                                    11          118724894     T       0.63   2.2 × 10^-8^    1.10   0.63   2.6 × 10^-8^    1.10   3.0 × 10^-15^   1.10   ***CXCR5***    intergenic
  rs12296430                                   12          6503500       C       0.19   3.6 × 10^-10^   1.14   0.21   1.7 × 10^-5^    1.09   7.2 × 10^-14^   1.12   ***LTBR***     intergenic
  rs4772201                                    13          100086259     A       0.82   1.7 × 10^-7^    1.12   0.83   1.1 × 10^-4^    1.09   1.3 × 10^-10^   1.10   *MIR548AN*     intergenic
  rs12148050                                   14          103263788     A       0.35   1.5 × 10^-5^    1.08   0.36   4.3 × 10^-9^    1.10   5.1 × 10^-13^   1.09   ***TRAF3***    intronic
  rs59772922                                   15          79207466      A       0.83   4.0 × 10^-6^    1.11   0.83   5.4 × 10^-4^    1.08   1.2 × 10^-8^    1.09   ***CTSH***     intergenic
  rs8042861                                    15          90977333      A       0.44   9.8 × 10^-7^    1.08   0.45   3.4 × 10^-4^    1.06   2.2 × 10^-9^    1.07   *IQGAP1*       intronic
  rs6498184                                    16          11435990      G       0.81   2.1 × 10^-10^   1.15   0.82   6.5 × 10^-9^    1.14   7.4 × 10^-18^   1.15   *RMI2*         intergenic
  rs7204270[\*](#TFN11){ref-type="table-fn"}   16          30156963      G       0.50   9.3 × 10^-8^    1.09   0.49   3.7 × 10^-5^    1.08   1.6 × 10^-11^   1.09   ***MAPK3***    intergenic
  rs1886700                                    16          68685905      A       0.14   8.8 × 10^-6^    1.11   0.14   3.2 × 10^-4^    1.08   1.3 × 10^-8^    1.10   *CDH3*         intronic
  rs12149527                                   16          79110596      A       0.47   1.7 × 10^-6^    1.08   0.47   4.3 × 10^-6^    1.08   3.3 × 10^-11^   1.08   *WWOX*         intronic
  rs7196953                                    16          79649394      A       0.29   2.6 × 10^-5^    1.08   0.30   7.9 × 10^-7^    1.09   1.0 × 10^-10^   1.09   *MAF*          intergenic
  rs12946510                                   17          37912377      A       0.47   8.5 × 10^-6^    1.08   0.48   8.0 × 10^-5^    1.07   2.9 × 10^-9^    1.07   ***IKZF3***    intergenic
  rs4794058                                    17          45597098      A       0.50   1.6 × 10^-5^    1.07   0.52   3.5 × 10^-10^   1.11   1.0 × 10^-13^   1.09   ***NPEPPS***   intergenic
  rs2288904                                    19          10742170      G       0.77   9.6 × 10^-10^   1.14   0.78   5.4 × 10^-4^    1.07   1.6 × 10^-11^   1.10   *SLC44A2*      exonic
  rs1870071                                    19          16505106      G       0.29   5.7 × 10^-10^   1.12   0.30   4.6 × 10^-7^    1.09   2.0 × 10^-15^   1.10   *EPS15L1*      intronic
  rs17785991                                   20          48438761      A       0.35   6.4 × 10^-7^    1.09   0.34   5.9 × 10^-3^    1.05   4.2 × 10^-8^    1.07   *SLC9A8*       intronic
  rs2256814                                    20          62373983      A       0.19   8.3 × 10^-7^    1.11   0.21   6.4 × 10^-4^    1.08   3.5 × 10^-9^    1.09   *SLC2A4RG*     intronic
  ***Secondary***                                                                                                                                                                  
  rs7769192[e](#TFN8){ref-type="table-fn"}     6           137962655     G       0.55   1.3 × 10^-5^    1.08   0.54   5.1 × 10^-5^    1.07   3.3 × 10^-9^    1.08                  intergenic
  rs533646[f](#TFN9){ref-type="table-fn"}      11          118566746     G       0.68   3.6 × 10^-7^    1.10   0.68   3.9 × 10^-5^    1.08   7.6 × 10^-11^   1.09   *TREH*         intergenic
  rs4780346[g](#TFN10){ref-type="table-fn"}    16          11288806      A       0.23   6.8 × 10^-6^    1.09   0.25   1.5 × 10^-5^    1.09   4.4 × 10^-10^   1.09   *CLEC16A*      intergenic

All listed signals had a discovery P-value ≤ 1.0 × 10^-4^, a replication P-value ≤ 5.0 × 10^-2^, and a joint P-value ≤ 5.0 × 10^-8^

All P-values are two-sided

RA= Risk Allele, RAF = Risk Allele Frequency

Position is based on human genome 19 and dbSNP 137.

Nearest gene listed if within 50Kb. Bold indicates Gene Ontology Immune System Process.

A proxy SNP (rs1036207, r^2^ = 0.99) and

(rs716719, r^2^=1.00) was used in replication.

The P-value and OR values provided are after conditioning on rs67297943 (Known -- see [Table 2](#T2){ref-type="table"}),

rs9736016, and

rs12927355 (Known -- see [Table 2](#T2){ref-type="table"}).

Note primary was rs11865086 (P-value = 1.77 × 10^-8^) in Discovery but not available in Replication so the best proxy was used.

###### 

49 Known non-MHC susceptibility loci associated with multiple sclerosis at a genome-wide significance level

                                                Discovery   Replication   Joint                                                                                                          
  --------------------------------------------- ----------- ------------- ------- ------ --------------- ------ ------ --------------- ------ ------------------- ------ --------------- ------------
  rs3748817                                     1           2525665       A       0.64   1.3 × 10^-12^   1.14   0.65   1.2 × 10^-15^   1.15   1.3 × 10^-26^       1.14   *MMEL1*         intronic
  rs41286801                                    1           92975464      A       0.14   7.9 × 10^-16^   1.20   0.16   2.1 × 10^-12^   1.17   1.4 × 10^-26^       1.19   *EVI5*          UTR3
  rs7552544[\*](#TFN19){ref-type="table-fn"}    1           101240893     A       0.56   3.7 × 10^-6^    1.08   0.43   3.3 × 10^-12^   1.12   1.9 × 10^-16^       1.10   ***VCAM1***     intergenic
  rs6677309                                     1           117080166     A       0.88   1.5 × 10^-28^   1.34   0.88   4.1 × 10^-16^   1.24   5.4 × 10^-42^       1.29   ***CD58***      intronic
  rs1359062                                     1           192541472     C       0.82   1.8 × 10^-13^   1.18   0.83   2.1 × 10^-8^    1.13   4.8 × 10^-20^       1.15   ***RGS1***      intergenic
  rs55838263                                    1           200874728     A       0.71   1.4 × 10^-9^    1.12   0.71   3.9 × 10^-11^   1.13   4.0 × 10^-19^       1.13   *C1orf106*      intronic
  rs2163226                                     2           43361256      A       0.71   7.0 × 10^-8^    1.10   0.73   3.8 × 10^-10^   1.14   2.1 × 10^-16^       1.12                   intergenic
  rs7595717                                     2           68587477      A       0.26   3.3 × 10^-7^    1.10   0.27   6.8 × 10^-8^    1.10   1.2 × 10^-13^       1.10   ***PLEK***      intergenic
  rs9989735                                     2           231115454     C       0.18   7.8 × 10^-14^   1.17   0.19   6.8 × 10^-11^   1.14   4.2 × 10^-23^       1.16   *SP140*         intronic
  rs2371108                                     3           27757018      A       0.38   2.1 × 10^-6^    1.08   0.39   5.8 × 10^-11^   1.12   1.5 × 10^-15^       1.10   ***EOMES***     downstream
  rs1813375                                     3           28078571      A       0.47   5.7 × 10^-18^   1.15   0.49   4.4 × 10^-16^   1.15   1.9 × 10^-32^       1.15                   intergenic
  rs1131265                                     3           119222456     C       0.80   2.0 × 10^-15^   1.19   0.81   4.8 × 10^-10^   1.14   1.4 × 10^-23^       1.17   *TIMMDC1*       exonic
  rs1920296[\*](#TFN19){ref-type="table-fn"}    3           121543577     C       0.64   6.8 × 10^-15^   1.14   0.64   5.5 × 10^-9^    1.10   6.5 × 10^-22^       1.12   *IQCB1*         intronic
  rs2255214[\*](#TFN19){ref-type="table-fn"}    3           121770539     C       0.52   5.3 × 10^-13^   1.13   0.52   3.3 × 10^-13^   1.13   1.2 × 10^-24^       1.13   ***CD86***      intergenic
  rs1014486                                     3           159691112     G       0.43   1.2 × 10^-9^    1.11   0.44   1.4 × 10^-10^   1.11   1.1 × 10^-18^       1.11   ***IL12A***     intergenic
  rs7665090                                     4           103551603     G       0.52   2.4 × 10^-6^    1.08   0.53   5.0 × 10^-4^    1.13   1.0 × 10^-8^        1.09   *MANBA*         intergenic
  rs6881706                                     5           35879156      C       0.72   4.9 × 10^-9^    1.12   0.73   1.7 × 10^-9^    1.12   4.3 × 10^-17^       1.12   ***IL7R***      intergenic
  rs6880778                                     5           40399096      G       0.60   1.7 × 10^-8^    1.10   0.61   3.9 × 10^-13^   1.13   8.1 × 10^-20^       1.12                   intergenic
  rs71624119                                    5           55440730      G       0.76   2.7 × 10^-9^    1.12   0.76   1.9 × 10^-5^    1.09   3.4 × 10^-13^       1.11   *ANKRD55*       intronic
  rs72928038                                    6           90976768      A       0.17   7.6 × 10^-7^    1.11   0.19   9.0 × 10^-11^   1.17   1.5 × 10^-15^       1.14   *BACH2*         intronic
  rs11154801                                    6           135739355     A       0.37   2.3 × 10^-9^    1.11   0.37   1.0 × 10^-12^   1.13   1.8 × 10^-20^       1.12   *AHI1*          intronic
  rs17066096                                    6           137452908     G       0.23   5.9 × 10^-12^   1.14   0.25   4.1 × 10^-13^   1.15   1.6 × 10^-23^       1.14   *IL22RA2*       intergenic
  rs67297943                                    6           138244816     A       0.78   4.8 × 10^-8^    1.12   0.80   2.5 × 10^-6^    1.11   5.5 × 10^-13^       1.11   ***TNFAIP3***   intergenic
  rs212405                                      6           159470559     T       0.62   1.4 × 10^-15^   1.15   0.64   1.8 × 10^-7^    1.10   8.0 × 10^-21^       1.12   *TAGAP*         intergenic
  rs1021156                                     8           79575804      A       0.24   5.6 × 10^-10^   1.12   0.26   2.1 × 10^-8^    1.11   8.5 × 10^-17^       1.11   *ZC2HC1A*       intergenic
  rs4410871                                     8           128815029     G       0.72   2.0 × 10^-9^    1.12   0.72   3.4 × 10^-8^    1.11   4.3 × 10^-16^       1.11   *MIR1204*       intergenic
  rs759648                                      8           129158945     C       0.31   2.8 × 10^-6^    1.09   0.31   3.7 × 10^-5^    1.08   5.0 × 10^-10^       1.08   *MIR1208*       intergenic
  rs2104286                                     10          6099045       A       0.72   7.6 × 10^-23^   1.21   0.73   3.6 × 10^-26^   1.23   2.3 × 10^-47^       1.22   ***IL2RA***     intronic
  rs1782645                                     10          81048611      A       0.43   4.3 × 10^-7^    1.09   0.41   6.2 × 10^-10^   1.11   2.5 × 10^-15^       1.10   *ZMIZ1*         intronic
  rs7923837                                     10          94481917      G       0.61   4.6 × 10^-9^    1.11   0.62   2.0 × 10^-9^    1.11   4.3 × 10^-17^       1.11   ***HHEX***      intergenic
  rs34383631                                    11          60793330      A       0.40   5.7 × 10^-10^   1.11   0.39   4.5 × 10^-15^   1.15   3.7 × 10^-23^       1.13   *CD6*           intergenic
  rs1800693                                     12          6440009       G       0.40   6.9 × 10^-16^   1.14   0.41   1.0 × 10^-13^   1.14   6.7 × 10^-28^       1.14   *TNFRSF1A*      intronic
  rs11052877                                    12          9905690       G       0.36   5.4 × 10^-9^    1.10   0.38   1.2 × 10^-5^    1.08   5.6 × 10^-13^       1.09   ***CD69***      UTR3
  rs201202118[c](#TFN17){ref-type="table-fn"}   12          58182062      A       0.67   7.4 × 10^-13^   1.14   0.67   1.6 × 10^-10^   1.12   9.0 × 10^-22^       1.13   *TSFM*          intronic
  rs7132277                                     12          123593382     A       0.19   1.9 × 10^-6^    1.10   0.19   1.4 × 10^-8^    1.13   1.9 × 10-^[@R13]^   1.12   *PITPNM2*       intronic
  rs2236262                                     14          69261472      A       0.50   1.2 × 10^-5^    1.08   0.50   3.8 × 10^-8^    1.09   2.5 × 10^-12^       1.08   ***ZFP36L1***   intronic
  rs74796499                                    14          88432328      C       0.95   8.5 × 10^-11^   1.31   0.95   4.5 × 10^-11^   1.33   2.4 × 10^-20^       1.32   *GALC*          intronic
  rs12927355                                    16          11194771      G       0.68   8.2 × 10^-27^   1.21   0.69   4.3 × 10^-21^   1.18   6.4 × 10^-46^       1.20   *CLEC16A*       intronic
  rs35929052                                    16          85994484      G       0.89   3.3 × 10^-7^    1.14   0.88   3.6 × 10^-6^    1.15   5.9 × 10^-12^       1.15   ***IRF8***      intergenic
  rs4796791                                     17          40530763      A       0.36   1.8 × 10^-8^    1.10   0.36   1.2 × 10^-13^   1.14   3.7 × 10^-20^       1.12   *STAT3*         intronic
  rs8070345                                     17          57816757      A       0.45   5.4 × 10^-16^   1.14   0.46   1.9 × 10^-9^    1.10   2.2 × 10^-23^       1.12   *VMP1*          intronic
  rs1077667                                     19          6668972       G       0.79   3.5 × 10^-13^   1.16   0.79   8.4 × 10^-13^   1.16   1.7 × 10^-24^       1.16   ***TNFSF14***   intronic
  rs34536443                                    19          10463118      C       0.95   1.2 × 10^-8^    1.28   0.96   2.9 × 10^-7^    1.30   1.8 × 10^-14^       1.29   ***TYK2***      exonic
  rs11554159                                    19          18285944      G       0.73   2.6 × 10^-13^   1.15   0.74   1.4 × 10^-12^   1.15   1.9 × 10^-24^       1.15   ***IFI30***     exonic
  rs8107548                                     19          49870643      G       0.25   2.0 × 10^-6^    1.09   0.26   2.5 × 10^-10^   1.13   5.7 × 10^-15^       1.11   *DKKL1*         intronic
  rs4810485                                     20          44747947      A       0.25   1.8 × 10^-5^    1.08   0.25   1.4 × 10^-12^   1.14   7.7 × 10^-16^       1.11   ***CD40***      intronic
  rs2248359                                     20          52791518      G       0.60   9.8 × 10^-5^    1.07   0.62   8.2 × 10^-11^   1.12   2.0 × 10^-13^       1.09   *CYP24A1*       intergenic
  rs2283792                                     22          22131125      C       0.51   1.1 × 10^-6^    1.08   0.53   5.4 × 10^-11^   1.11   5.5 × 10^-16^       1.10   ***MAPK1***     intronic
  ***Secondary***                                                                                                                                                                        
  rs523604[d](#TFN18){ref-type="table-fn"}      11          118755738     A       0.53   2.5 × 10^-7^    1.09   0.54   4.0 × 10^-9^    1.11   6.2 × 10^-15^       1.10   ***CXCR5***     intronic

All listed signals had a discovery P-value ≤ 1.0 × 10^-4^, a replication P-value ≤ 5.0 × 10^-2^, and a joint P-value ≤ 5.0 × 10^-8^

All P-values are two-sided

RA = Risk Allele, RAF = Risk Allele Frequency

Position is based on human genome 19 and dbSNP 137.

Nearest gene listed if within 50Kb. Bold indicates Gene Ontology Immune System Process.

A proxy SNP (rs10431552, r^2^ = 0.99) was used in replication.

The P-value and OR values provided are after conditioning on rs9736016 and rs533646 (both Novel -- see [Table 1](#T1){ref-type="table"}).

These three SNPs were not primary in the 2011 GWAS, two were secondary and the third was tertiary in that study.

###### 

The 18 variants from the 8 regions with consistent high resolution fine-mapping

  Gene                                         SNP          Chr         Position[a](#TFN22){ref-type="table-fn"}   Posterior   GERP                                      Functional Annotation[b](#TFN23){ref-type="table-fn"}
  -------------------------------------------- ------------ ----------- ------------------------------------------ ----------- ----------------------------------------- -----------------------------------------------------------------------
  *TNFSF14*                                    rs1077667    19          6668972                                    0.74        -3.89                                     intronic, TFBS / DNase1 peak, correlates with serum levels of TNFSF14
  *IL2RA*                                      rs2104286    10          6099045                                    0.93        -0.47                                     intronic, correlates with soluble IL-2RA levels
  *TNFRSF1A*                                   rs1800693    12          6440009                                    0.69        2.53                                      intronic, causes splicing defect and truncated soluble TNFRSF1A
  rs4149580[c](#TFN24){ref-type="table-fn"}    12           6446990     0.10                                       2.06        intronic                                  
  *IL12A*                                      rs1014486    3           159691112                                  0.67        0.24                                      \-
  *CD6*                                        rs34383631   11          60793330                                   0.20        1.66                                      \-
  rs4939490[c](#TFN24){ref-type="table-fn"}    11           60793651    0.14                                       -0.53       \-                                        
  rs4939491[c](#TFN24){ref-type="table-fn"}    11           60793722    0.14                                       -0.37       \-                                        
  rs4939489                                    11           60793648    0.10                                       3.25        \-                                        
  *TNFAIP3*                                    rs632574     6           137959118                                  0.27        -1.15                                     \-
  rs498549[c](#TFN24){ref-type="table-fn"}     6            137984935   0.20                                       0.52        \-                                        
  rs651973                                     6            137996134   0.17                                       2.41        downstream of RP11-95M15.1 lincRNA gene   
  rs536331                                     6            137993049   0.15                                       0.19        upstream of RP11-95M15.1 lincRNA gene     
  *CD58*                                       rs6677309    1           117080166                                  0.21        -1.18                                     intronic, TFBS / DNase1 peak
  rs35275493[c](#TFN24){ref-type="table-fn"}   1            117095502   0.24                                       0.75        intronic (insertion)                      
  rs10754324[c](#TFN24){ref-type="table-fn"}   1            117093035   0.22                                       0.32        intronic                                  
  rs1335532                                    1            117100957   0.17                                       -1.32       intronic                                  
  *STAT4*                                      rs78712823   2           191958581                                  0.59        -3.98                                     intronic

All listed variants have posterior ≥ 0.1 in regions where ≤ 5 variants explain the top 50% of the posterior and the top SNP from the frequentist analysis lives in the 90% confidence interval, ordered by maximum posterior.

Posterior denotes the posterior probability of any variant driving association. GERP denotes Genomic Evolutionary Rate Profiling.

Position is based on human genome 19 and dbSNP 137.

Functional data from VEP, eQTL browser, Fairfax et al. (2012), pubmed searches, 1000G. Dash indicates intergenic with no additional annotation. Variants without annotation are intergenic and have no reported regulatory consequence.

Imputed variant.

[^1]: These authors contributed equally to this work.
